StockData

CervoMed vs Jupiter Neurosciences

CRVO and JUNS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRVO and JUNS compare

CervoMed is the larger company, worth 19 times as much as Jupiter Neurosciences ($25.2M against $1.3M).

CervoMed scores higher on the StockData Score (5 against 0 for Jupiter Neurosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRVOJUNS
Size and price
Market cap$25.2M$1.3M
Share price$1.67$1.70
Change, 1 year−77.0%−98.3%
Change, 5 years−94.3%–
Beta (5Y)3.26−0.18
Employees155
StockData Score
Total score5 (better)0
Valuation score1 (better)0
Growth score00
Performance score00
Health score4 (better)0
Dividend score00
Valuation
P/S76.2×–
P/B1.1×–
Growth
Revenue growth (TTM)−95.7%–
Profitability
Operating margin−9407%–
Net margin−9161%–
Return on equity−108% (better)−1889%
Financial health
Debt / equity0.00–
Interest coverage–−36.0×
Current ratio–0.66
Altman Z-score−4.99 (better)−23.63
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions11.6%2.2%
Held by insiders36.9%–
Insider net buying, 12 months$3.0M–
Short interest, % of float12.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.